CADM2 and non-small cell lung carcinoma: The silencing of CADM2 in several NSCLC cell lines (e.g., A549 and H322) resulted in lower vimentin levels, accompanied by a decrease in cell migratory ability and an increase in the expression of epithelial marker E-cadherin.